Výsledky vyhledávání

P607 Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open

Autor: D T Rubin, S R Vavricka, A Armuzzi, M C Dubinsky, A I Sharara, I Modesto, M Fellmann, G Liguori, N Lawendy, M J Cadatal, G R Lichtenstein

Publikováno v: Journal of Crohn's and Colitis. 16:i538-i539

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Data from OCTAVE Induction 1&2 and OCTAVE Sustain demonstrated that a history of extraintestinal manifestations (EIMs) was shown not to infl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8198513af5e662a6e854e4aa23e396b
https://doi.org/10.1093/ecco-jcc/jjab232.733

Zobrazit plný text záznamu

P563 Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme

Autor: D T Rubin, J Torres, M Regueiro, W Reinisch, L Prideaux, P G Kotze, F H Tan, S Gardiner, R Mundayat, M J Cadatal, S C Ng

Publikováno v: Journal of Crohn's and Colitis. 16:i506-i507

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib were evaluated in randomised, placebo-controlled Phase (P)2 (NCT00787202) and P3 (NCT01465763; NCT0145895

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74d2b2b64f4d012b4e1c22b6aebb1f42
https://doi.org/10.1093/ecco-jcc/jjab232.689

Zobrazit plný text záznamu

POS0671 IMPACT OF RACE ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, 3 AND 3B/4 CLINICAL TRIALS

Autor: G. C. Wright, E. Mysler, Y. H. Chen, C. Kinch, A. Yndestad, K. Kwok, M. J. Cadatal, R. Germino, A. Ogdie

Publikováno v: Annals of the Rheumatic Diseases. 81:609-609

BackgroundWhile racial disparities in clinical outcomes for rheumatoid arthritis (RA) patients (pts) have been described,1 there is a paucity of data on racial differences in response to advanced therapies.ObjectivesTo evaluate impact of self-reporte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3fb91902acd7973a3aac7a96cfd97c19
https://doi.org/10.1136/annrheumdis-2022-eular.716

Zobrazit plný text záznamu

P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab

Autor: Bernd Bokemeyer, M J Cadatal, Javier P. Gisbert, Heather Fowler, Matthieu Allez, Shahrzad Moosavi, Raymond Cheung, Pamela Selema, Milan Lukas, Tibor Hlavaty

Publikováno v: Journal of Crohn's and Colitis. 13:S410-S410

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75970c38624346b0fa8bc621fca35c7d
https://doi.org/10.1093/ecco-jcc/jjy222.714

Zobrazit plný text záznamu

Akademický článek

Retraction: An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab

Publikováno v: Journal of Crohn's & Colitis. Mar2020, Vol. 14 Issue 3, p428-428. 1p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání